{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Ajanta Pharma Ltd.
Ajanta Pharma Gains 3.08%: 2 Key Factors Driving the Weekly Rally
Ajanta Pharma Ltd. delivered a solid performance in the week ending 31 July 2026, with its stock rising 3.08% compared to the Sensex’s 2.39% gain. The week was marked by strong quarterly results and an upgraded financial outlook, which supported the stock’s resilience amid mixed market conditions. Despite some volatility midweek, Ajanta Pharma’s shares closed near their recent highs, reflecting investor confidence in the company’s growth trajectory.
Has Ajanta Pharma Ltd. declared dividend?
Yes, Ajanta Pharma Ltd. has declared a dividend of 1600%, amounting to ₹28.04 per share, with an ex-date of August 5, 2026. The company has demonstrated strong total returns across various periods, reflecting solid performance and shareholder value.
Are Ajanta Pharma Ltd. latest results good or bad?
Ajanta Pharma Ltd. reported strong financial results for June 2026, with net sales growing 24.82% to ₹1,625.96 crores and net profit increasing 30.89% to ₹334.22 crores, despite slight margin compression. Overall, the results indicate robust operational performance and a solid balance sheet, positioning the company favorably in the pharmaceutical sector.
Ajanta Pharma Ltd. Reports Strong Quarterly Growth, Upgrades Financial Outlook
Ajanta Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a marked improvement in its financial performance for the quarter ended June 2026. The company’s recent upgrade from Hold to Buy by MarketsMOJO reflects its robust revenue growth, margin expansion, and positive financial trend reversal, signalling renewed investor confidence amid a challenging market backdrop.
Ajanta Pharma Q1 FY27: Stellar Quarter Drives 31% Profit Surge
Ajanta Pharma Ltd., a mid-cap specialty pharmaceutical formulation company with a market capitalisation of ₹42,566 crores, reported a robust performance for Q1 FY27, with consolidated net profit surging 30.89% year-on-year to ₹334.22 crores from ₹255.34 crores in Q1 FY26. On a sequential basis, the company posted an even stronger 25.32% quarter-on-quarter growth from ₹266.70 crores in Q4 FY26, marking the highest quarterly profit in the company's recent history.
Ajanta Pharma Ltd Gains 1.53% Early Week Before Profit-Taking Pullback: 4 Key Factors Driving the Move
Ajanta Pharma Ltd exhibited a mixed performance during the week ending 24 July 2026, opening strong with a 1.53% gain on 20 July and reaching new 52-week and all-time highs on 21 and 22 July. However, the latter part of the week saw profit-taking pressures, with the stock closing at Rs.3,366.45 on 24 July, down 2.16% on the day and ending the week with a modest decline of 1.47%. This contrasted with the broader Sensex, which fell 1.85% over the same period, indicating relative outperformance despite the late-week weakness.
Ajanta Pharma Ltd. is Rated Hold by MarketsMOJO
Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 March 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 23 July 2026, providing investors with an up-to-date view of the company’s performance and outlook.
Broad-Based Technical Strength Lifts Ajanta Pharma Ltd. to 52-Week High of Rs 3598.4
From a 52-week low of Rs 2,335 to a fresh peak of Rs 3,598.4 on 22 Jul 2026, Ajanta Pharma Ltd. has delivered a robust 26.8% gain over the past year, outpacing the Sensex’s decline of 6.4%. This milestone reflects a sustained uptrend fuelled by a confluence of bullish technical indicators and steady price momentum.
Ajanta Pharma Ltd: Valuation Shifts Signal Changing Price Attractiveness Amid Strong Returns
Ajanta Pharma Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from expensive to very expensive territory. Despite this, the stock has delivered robust returns well above the Sensex benchmark, prompting a reassessment of its price attractiveness and investment stance.
When is the next results date for Ajanta Pharma Ltd.?
Ajanta Pharma Ltd. will announce its results on 30 July 2026.
Broad-Based Technical Strength Lifts Ajanta Pharma Ltd. to 52-Week High of Rs 3548.9
Ajanta Pharma Ltd. has surged to a new 52-week and all-time high of Rs 3,548.9 on 21 Jul 2026, marking a significant milestone in its price momentum. This advance comes amid a backdrop of strong technical signals across multiple timeframes, underscoring the stock’s robust upward trajectory despite a broadly subdued market environment.
Ajanta Pharma Ltd. Hits All-Time High of Rs 3,520 as Momentum Builds Across Timeframes
Ajanta Pharma Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has reached a new all-time high in its stock price on 21 July 2026, underscoring its robust market performance and sustained growth trajectory.
Ajanta Pharma Ltd. is Rated Hold
Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 March 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 12 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Ajanta Pharma Ltd. Falls 1.54% Despite New 52-Week Highs: 3 Key Factors Driving the Week
Ajanta Pharma Ltd. experienced a volatile week from 29 June to 3 July 2026, opening at Rs.3,377.90 and closing lower at Rs.3,325.75, marking a weekly decline of 1.54%. This contrasted with the broader Sensex, which gained 1.31% over the same period, highlighting a relative underperformance despite the stock hitting multiple new 52-week highs during the week. Key events included a strong intraday surge on 29 June, a fresh 52-week high on 1 July, and a subsequent mild pullback, reflecting mixed investor sentiment amid robust technical momentum.
Ajanta Pharma Ltd. is Rated Hold by MarketsMOJO
Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Broad-Based Technical Strength Lifts Ajanta Pharma Ltd. to 52-Week High of Rs 3505.55
With a decisive breakthrough to Rs 3505.55 on 1 Jul 2026, Ajanta Pharma Ltd. has reached a fresh 52-week high, extending its impressive 35.92% gain over the past year against the Sensex’s decline of 8.32%. This milestone reflects a strong alignment of technical indicators and sustained price momentum that has propelled the stock well above key moving averages.
Ajanta Pharma Ltd. Surges 7.76% to Day's High of Rs 3425 — Outperforms Sector by 5.73 Percentage Points
The Sensex declined 0.57% on 29 Jun 2026 while Ajanta Pharma Ltd. surged 7.76%, marking a 5.73 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers. This sharp single-session gain rewrites the short-term narrative for the small-cap stock, which also touched a new 52-week high of Rs 3425 during the day.
Broad-Based Technical Strength Lifts Ajanta Pharma Ltd. to 52-Week High of Rs 3330
Ajanta Pharma Ltd. has surged to a fresh 52-week high of Rs 3330 on 29 Jun 2026, marking a significant milestone in its price momentum. This advance comes amid a backdrop of strong technical signals and sustained outperformance relative to its sector and the broader market.
Ajanta Pharma Ltd. is Rated Hold
Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 June 2026, providing investors with the latest insights into its performance and outlook.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
